The Dutch group Qiagen, a CataloniaBio & HealthTech member, has expanded its facilities in the Barcelona Science Park (PCB) to 2,800 square metres to double its production capacity for Covid-19 diagnosis tests.
The inauguration took place on 23 November, in the presence of the Minister of Business and Knowledge of the Government of Catalonia, Ramon Tremosa; Rector of the University of Barcelona, Joan Elias; the head of Qiagen Barcelona, Nik Baumann, CEO of the PCB, Maria Terrades; Universities and Research Secretary, Francesc Xavier Grau; General Director of Research, Joan Gómez; and the Secretary of Business and Competition, Quim Ferrer.
The test known as QIAstat-Dx has been developed based on technology from the Catalan start-up Stat-Dx, which the multinational bought out in 2018. QIAstat-Dx is currently on sale in over 70 countries.
Qiagen has a team of 200 people in Barcelona including plant operators, engineers and researchers. The company plans to continue investing in this production plant and in R&D.
Photo: Nik Baumann, head of Qiagen Barcelona - © Qiagen
Comments